ECELLFrance Publications


2022 - 4 publications

Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study

Farge D, Loisel S, Resche-Rigon M, Lansiaux P, Colmegna I, Langlais D, Catney C, Pugnet G, Thibault A, Maria J, Chatelus E, Martin T, Hachulla E, Kheav VD, Lambert N, Wang HC, Michonneau D, Martinaud C, Sensebé L, Tarte K.

The Lancet Rheum. 2022 FEB 4(2)91-104. doi: 10.1016/S2665-9913(21)00326-X. IF 8.1

Download
CD40L-expressing CD4+ T cells prime adipose-derived stromal cells to produce inflammatory chemokines
Dulong J, Loisel S, Rossille D, Léonard S, Bescher N, Bezier I, Latour M, Monvoisin C, Monnier D, Bertheuil N, Roulois D, Tarte K.
Cytotherapy. 2022 Feb 23;S1465-3249(22)00021-4. doi: 10.1016/j.jcyt.2022.01.006. IF 5.4
Dulong et al. 2022.pdf
Adobe Acrobat Document 1.7 MB
Download

Quality assessment of a serum and xenofree medium for the expansion of human GMP-grade mesenchymal stromal cells.

Aussel C, Busson E, Vantomme H, Tissèdre F, Peltzer J, Martinaud C.

Submitted to Peer J. IF 3

Intra-articular delivery of full-length antibodies through the use of an in situ forming depot

Fayd’herbe de Maudave A, Leconet W, Toupet K, Constantinides M, Bossis G, De Toledo M, Vialaret J, Hirtz C, Loez-Noriega A, Jorgensen C, Noel D, Louis-Plence P, Grizot S, and Vilalba M.

Journal of Controlled Release 2022 341:578-590. doi: 10.1016/j.jconrel.2021.12.010. IF 9.8